Fundraising Fox

Fuse Vectors

Founded 2022 · 10 employees on LinkedIn · 1 known investors

Fuse Vectors develops a cell-free viral vector manufacturing technology that produces AAVs outside of cells for use in gene therapy. The modular process aims to lower production costs, improve purity, and shorten development timelines for gene therapy developers.

BiotechDeep TechHealthtech

Investors · 1

HCVCParis · $100K – $1M

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Fuse Vectors secures $5.2m to advance cell-free gene therapy technology, led by HCVC - Green Prophetgreenprophet.com · Feb 2025Danish startup secures $5.2M in pre-seed funding to streamline gene therapy production - ArcticStartuparcticstartup.com · Feb 2025Fuse Vectors secures USD 5.2 million | Startbasestartbase.com · Feb 2025Making Gene Therapy Faster And Better With Fuse Vectorsforbes.com · Feb 2025Fuse Vectors secures over €4.9 million for gene therapy with its cell-free viral vector technology | EU-Startupseu-startups.com · Feb 2025Fuse Vectors secures $5.2m to advance cell-free gene therapy technology, led by HCVCglobenewswire.com · Feb 2025

Frequently asked questions

What does Fuse Vectors do?
Fuse Vectors develops a cell-free viral vector manufacturing technology that produces AAVs outside of cells for use in gene therapy. The modular process aims to lower production costs, improve purity, and shorten development timelines for gene therapy developers.
Who are Fuse Vectors's investors?
Fuse Vectors's investors include HCVC.